,i #aaith ,,congress #ast ,session ,h4 ,r4 #cdic ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjbe ,mr4 ,khanna 7for himself1 ,mrs4 ,luna1 ,ms4 ,kaptur1 and ,mr4 ,biggs of ,arizona7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,ways and ,means1 and the ,judiciary1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to reduce prescription drug prices by aligning ,u4,s4 prices with international benchmarks4 #a4 ,short title ,this ,act may be cited as the ,global ,fairness in ,drug ,pricing ,act4 #b4 ,drug pricing 7a7 ,most-favored nation price targets ,not later than #cj days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall1 in coordination with the ,administrator of the ,centers for ,medicare ,medicaid ,services and other heads of relevant ,federal agencies--propose a rulemaking plan to impose most-favored-nation price targets to pharmaceutical manufacturers to ensure that prices for pharmaceutical products paid by patients in the ,united ,states are comparable to the prices for such products paid by comparably developed countries4 7b7 ,importation by individuals ,the ,secretary of ,health and ,human ,services shall certify to ,congress that importation under section #hjd7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #chd7;j77 will pose no risk to the health and safety of the public and will result in a significant reduction in the cost of prescription drugs to the ,american patients in the ,united ,states2 and the ,secretary of ,health and ,human ,services shall take action under section #hjd7;j77#b77;,b7 of such ,act to describe circumstances under which waivers will be consistently granted to individuals to import prescription drugs1 on a case-by-case basis1 from developed countries with low-cost prescription drugs4 7c7 ,enforcement actions ,the ,attorney ,general and the ,chair of the ,federal ,trade ,commission shall1 to the extent consistent with law1 undertake enforcement action against any anticompetitive practices by pharmaceutical manufacturers1 including through enforcement of sections #a and #b of the ,sherman ,act 7#ae ,u4,s4,c4 #a1 #b7 and section #e of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #de71 as appropriate4 7d7 ,programs enabling direct-to-,consumer purchases ,to the extent permitted by law1 the ,secretary of ,health and ,human ,services shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their pharmaceutical products to patients in the ,united ,states at the prices determined through the rulemaking under subsection 7a74 7e7 ,study of unreasonable or discriminatory behaviors of manufacturers ,the ,secretary of ,commerce and the ,united ,states ,trade ,representative shall conduct a study to determine whether any act1 policy1 or practice by pharmaceutical manufacturers constitutes unreasonable or discriminatory behavior that-- 7#a7 impairs national security2 7#b7 forces patients in the ,united ,states to subsidize global pharmaceutical research and development2 or 7#c7 involves suppression of drug prices in foreign markets below fair market value4 ,the findings of such a study shall be submitted in a report to ,congress not later than #ahj days after the date of the enactment of this ,act4